Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical has filed a complaint in the US District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterisation of Copaxone (glatiramer acetate injection) will will expire latest in February 2020.
Subscribe to our email newsletter
Glatiramer acetate is an immunomodulator drug for currently used to treat multiple sclerosis.
Copaxone is a random polymer of four amino acids found in myelin basic protein, namely glutamic acid, lysine, alanine, and tyrosine, and may work as a decoy for the immune system.
Teva previously filed a separate lawsuit against Mylan in October 2009 for infringement of multiple patents, including all seven Orange Book patents, covering the chemical composition of Copaxone, pharmaceutical compositions containing it, methods of using it and processes for making it.
Teva said that those patents expire in May 2014 and September 2015.